Methicillin resistance among clinical isolates of Staphylococcus aureus in Egypt

May 26, 2017

About 40-70% of the infections caused by Staphylococcus aureus strains are due to methicillin resistant ones. These isolates are usually multi-drug resistant and harder to treat endangering hundreds of thousands of patients worldwide and costing billions in added health care costs. Accurate numbers describing the prevalence and characteristics of these infections and the added burden they cause to developing countries in the eastern Mediterranean and African regions are lacking. Egypt is no exception. In this article that appeared in Infectious Disorders - Drug Targets, Dr. AlaaAbouelfetouh, Associate Professor of Microbiology at the Faculty of Pharmacy, Alexandria University, is gathering the published data describing methicillin resistance in S. aureus (MRSA) in Egypt.

The reports described a general MRSA prevalence rate of 50-82% among hospitalized patients mainly in the largest two Egyptian cities Cairo and Alexandria and a lower rate of 24% in Minia, an important but less populated city in southern Egypt. The articles that investigated community acquired MRSA reported 19-47% prevalence. Some of these studies molecularly characterized the types of the MRSA isolates using different techniques; SCCmec typing, or spa typing and Multi-locus sequence typing (MLST). SCCmec types V, IV and its subtypes were detected in two separate studies. A different study revealed a MRSA prevalence rate among retail chickens of 38% which could act as reservoir for resistance transfer to humans.

"Although the numbers point to an increasing rate of MRSA occurrence, especially in large cities such as Cairo and Alexandria, in the absence of a national surveillance program it is not possible to extrapolate these results to cover the whole country", warns Dr. Abouelfetouh.

Despite these alarming levels of MRSA in hospital and community settings, awareness of MRSA control measures among the medical staff at one of the major health centers in Egypt was at the 67% level.
For more information about the article, please visit

Reference: Abouelfetouh A. (2017). The Status of Methicillin Resistance Among Egyptian Staphylococcus aureus Isolates: An Overview, Infectious Disorders - Drug Targets., DOI: 10.2174/1871526516666160802111200

Bentham Science Publishers

Related MRSA Articles from Brightsurf:

Widely available antibiotics could be used in the treatment of 'superbug' MRSA
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research from an international collaboration led by scientists at the University of Cambridge and the Wellcome Sanger Institute.

Computer model shows how to better control MRSA outbreaks
A research team led by scientists at the Columbia University Mailman School of Public Health report on a new method to help health officials control outbreaks of methicillin-resistant Staphylococcus aureus, or MRSA, a life-threatening antibiotic-resistant infection often seen in hospitals.

Using MRSA's strength against it
MRSA evolved to become a deadly killer because it's wily and resilient.

Livestock-associated MRSAfound among MRSA from humans
The survey results show more frequent detections and geographical dispersion of LA-MRSA in humans in the EU/EEA since 2007, and highlight the public health and veterinary importance of LA-MRSA as a 'One Health' issue.

Fighting MRSA with new membrane-busting compounds
Public health officials are increasingly concerned over methicillin-resistant Staphylococcus aureus (MRSA).

Know thy enemy: Kill MRSA with tailored chemistry
UConn medicinal chemists have developed experimental antibiotics that kill MRSA, a common and often deadly bacteria that causes skin, lung, and heart infections.

MRSA uses decoys to evade a last-resort antibiotic
The superbug MRSA uses decoys to evade a last-resort antibiotic, reveals new research.

Scientists find a salty way to kill MRSA
Scientists have discovered a new way to attack Staphylococcus aureus bacteria.

Experimental antibiotic treats deadly MRSA infection
A new experimental antibiotic developed by a team of scientists at Rutgers University successfully treats the deadly MRSA infection and restores the efficacy of a commonly prescribed antibiotic that has become ineffective against MRSA.

OU team develops new antibiotic to fight MRSA
A University of Oklahoma team of chemists has developed a new antibiotic formulation to fight the sometimes deadly staph infection caused by methicillin-resistant S. aureus or MRSA and other antibiotic-resistant infectious bacteria.

Read More: MRSA News and MRSA Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to